Gloriane W. Schnabolk, Ph.D.
Affiliations: | 2009 | Medical University of South Carolina, Charleston, SC, United States |
Area:
Molecular Biology, Pharmacology, Pharmaceutical ChemistryGoogle:
"Gloriane Schnabolk"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Douglas H. Sweet | grad student | 2009 | MUSC | |
| (Characterization of the murine organic anion transporter Oat6 (Slc22a20): Insight to its role in the olfactory mucosa and testes.) | ||||
| Bärbel Rohrer | post-doc | MUSC (Neurotree) | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Schnabolk G, Obert E, Banda NK, et al. (2021) Systemic Inflammation by Collagen-Induced Arthritis Affects the Progression of Age-Related Macular Degeneration Differently in Two Mouse Models of the Disease. Investigative Ophthalmology & Visual Science. 61: 11 |
| Schnabolk G. (2020) Systemic Inflammatory Disease and AMD Comorbidity. Advances in Experimental Medicine and Biology. 1185: 27-31 |
| Schnabolk G, Rohrer B, Simpson KN. (2019) Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis. Investigative Ophthalmology & Visual Science. 60: 3520-3526 |
| Parsons N, Annamalai B, Obert E, et al. (2019) Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization. Molecular Immunology. 108: 8-12 |
| Schnabolk G, Parsons N, Obert E, et al. (2018) Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization. Molecular Therapy. Methods & Clinical Development. 9: 1-11 |
| Schnabolk G, Beon MK, Tomlinson S, et al. (2017) New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics |
| Rohrer B, Schnabolk G, Annamalei B, et al. (2017) Delivery of CR2-fH using AAV vector therapy and encapsulated cell technology as treatment strategies in mouse model of neovascularization Molecular Immunology. 89: 202 |
| Woodell A, Jones BW, Williamson T, et al. (2016) A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Investigative Ophthalmology & Visual Science. 57: 1728-37 |
| Coughlin B, Schnabolk G, Joseph K, et al. (2016) Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and γδT-cells. Scientific Reports. 6: 23794 |
| Schnabolk G, Coughlin B, Joseph K, et al. (2015) Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Investigative Ophthalmology & Visual Science. 56: 1850-63 |